CJC-1295 + Ipamorelin Canada | Research Guide
Share
Canada Research Guide Research Use Only Updated June 2026
CJC-1295 + Ipamorelin Canada Research Guide
CJC-1295 + Ipamorelin is the most commonly requested growth hormone secretagogue combination in Canadian peptide research. This guide covers how each compound works individually, why the dual-pathway combination is studied, published pharmacological data, purity considerations for blended peptides, and sourcing guidance for researchers in Canada.
Direct Answer: CJC-1295 is a modified GHRH (growth hormone-releasing hormone) analog that extends GH pulse duration through albumin binding. Ipamorelin is a selective ghrelin/GHSR agonist that initiates GH release without significant effects on cortisol, prolactin, or ACTH. The combination is studied for its dual-pathway approach: GHRH-mediated pulse extension combined with ghrelin-mediated pulse initiation. For Canadian researchers, key sourcing criteria are ≥99% purity with third-party HPLC/MS verification for both compounds in the blend, batch-specific COAs, and domestic shipping.
Jump to a section
What Is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is a pre-blended combination of two growth hormone secretagogue peptides designed to activate complementary GH release pathways. Rather than directly providing exogenous growth hormone, both compounds stimulate the body's endogenous GH production through different receptor systems.
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Peptide class | Modified GHRH analog | Selective GHSR agonist |
| Receptor target | GHRH receptor | Ghrelin/GHS receptor |
| Primary action | Extends GH pulse duration | Initiates discrete GH pulses |
| Half-life | Extended (~8 days with DAC) | Short (~2 hours) |
| Cortisol/prolactin effects | Minimal at physiological doses | None (key selectivity advantage) |
CJC-1295: GHRH Receptor Pharmacology
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that enables covalent binding to serum albumin. This albumin binding dramatically extends the peptide's half-life from minutes (native GHRH) to approximately 8 days, allowing sustained GHRH receptor activation.
Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006, PMID: 16384846) demonstrated that CJC-1295 produced sustained elevations in GH and IGF-1 levels following single and multiple administrations, with the DAC modification enabling once-weekly or less frequent research protocols.
The GHRH receptor pathway is distinct from the ghrelin receptor pathway — CJC-1295 extends the duration of GH pulses that have already been initiated, rather than triggering new pulses. This is why it is combined with a ghrelin-pathway agonist like ipamorelin.
Ipamorelin: Selective GH Secretagogue
Ipamorelin is a synthetic pentapeptide that selectively activates the growth hormone secretagogue receptor (GHSR/ghrelin receptor) to stimulate pulsatile GH release. Its key research distinction is selectivity: unlike earlier ghrelin-pathway agonists such as GHRP-6 and GHRP-2, ipamorelin does not significantly affect cortisol, prolactin, or ACTH levels at GH-stimulating concentrations.
Raun et al. (European Journal of Endocrinology, 1998, PMID: 9893259) established ipamorelin's selectivity profile, demonstrating potent GH release without the cortisol and prolactin elevations seen with GHRP-6. This selectivity makes ipamorelin the preferred ghrelin-pathway research compound for GH secretagogue studies.
Johansen et al. (Growth Hormone & IGF Research, 1999, PMID: 10421362) further characterized ipamorelin's GH-releasing properties and confirmed its selectivity advantage over non-selective secretagogues.
Why the Combination Is Studied
The CJC-1295 + Ipamorelin combination targets two complementary pathways in the GH axis:
| Pathway | Component | Role |
|---|---|---|
| Pulse initiation | Ipamorelin (GHSR) | Triggers discrete GH release events via ghrelin receptor |
| Pulse extension | CJC-1295 (GHRH-R) | Extends the amplitude and duration of each GH pulse |
| Combined effect | Both | Studied for whether dual-pathway activation produces synergistic GH elevation vs either compound alone |
This dual-pathway hypothesis is the central research question for CJC-1295 + Ipamorelin: whether combined GHRH-R and GHSR activation produces GH profiles that differ qualitatively from single-pathway approaches. The pre-blended 5mg/5mg format facilitates this combination research.
Key Published Studies
| Study | Focus | Key Finding |
|---|---|---|
| Raun et al., 1998 (PMID: 9893259) | Ipamorelin selectivity | Demonstrated potent GH release without cortisol/prolactin/ACTH elevation |
| Teichman et al., 2006 (PMID: 16384846) | CJC-1295 pharmacology | Sustained GH and IGF-1 elevation with extended half-life via DAC albumin binding |
| Johansen et al., 1999 (PMID: 10421362) | Ipamorelin GH release | Characterized dose-dependent GH release and confirmed selectivity vs GHRP-6 |
Purity Considerations for Blended Peptides
Pre-blended peptide products like CJC-1295 + Ipamorelin present additional quality verification challenges because both compounds must be independently verified within the blend.
| Quality Signal | Why It Matters for Blends |
|---|---|
| ≥99% purity (HPLC) | Must verify both peptides independently in the blend |
| Mass spectrometry | Confirms molecular identity of both CJC-1295 and Ipamorelin |
| Ratio verification | Ensures the stated 5mg/5mg blend ratio is accurate |
| Third-party testing | Independent lab verification through Testides (Toronto) |
Storage and Handling
| Condition | Recommendation |
|---|---|
| Lyophilized (unopened) | -20°C long-term; 2-8°C short-term |
| Reconstituted | 2-8°C, use within 21 days |
| Solvent | Bacteriostatic water |
Reconstitution guide → | Bacteriostatic Water | Insulin Syringes
Source CJC-1295 + Ipamorelin from a Canadian Supplier
CJC-1295 + Ipamorelin 10mg — $79 CAD Shipping PolicyFrequently Asked Questions
What is CJC-1295 + Ipamorelin used for in research?
Why use a blend instead of individual compounds?
What makes ipamorelin different from GHRP-6?
What purity should I look for in blended peptides?
How should CJC-1295 + Ipamorelin be stored?
Does ThePeptide.ca ship CJC-1295 + Ipamorelin across Canada?
Related Research Resources
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. PubMed: 9893259
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. PubMed: 16384846
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. PubMed: 10421362
For laboratory and research use only. ThePeptide.ca materials are not represented as approved for human use, veterinary use, or therapeutic application.
Shop This Compound
Every batch is third-party lab tested with a published COA, shipped same-day from BC: CJC-1295 + Ipamorelin 10mg. Browse the full collection →
Related Research Guides
Where to buy peptides in Canada · How to reconstitute peptides